HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RB Eyes UK VMS Market With Optrex ProVision Supplement

Executive Summary

Reckitt Benckiser launches a new Optrex eye-health food supplement and extends its Screen Eyes campaign for the brand in the UK.

You may also be interested in...

Reckitt's New CEO Wants Immediate Changes As OTC Sales Slump In Q3

RB's new CEO Laxman Narasimhan is unforgiving about how the company has been run over the past few years and believes things need to change after another disappointing quarter. 

RB Targets UK’s Hedonistic ‘Generation Z’ With Ironic Gaviscon Campaign

Reckitt Benckiser extends its "Night Labs" Gaviscon campaign aimed at UK 20-something heartburn sufferers with two new tongue in cheek videos.

Reckitt Charges Into UK PPI Heartburn Space With Guardium

With its new esomeprazole-based heartburn and indigestion remedy, Guardium, Reckitt Benckiser is taking head on Pfizer’s well-established Nexium Control brand in the UK. The firm hopes that by associating Guardium with its own well-known heartburn brand Gaviscon, and by investing in a multi-million-pound marketing campaign and pharmacy education, it can carve for itself a significant slice of the UK’s gastrointestinal market.  

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts